These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 11907196)

  • 21. Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver.
    Al-Jahdari WS; Yamamoto K; Hiraoka H; Nakamura K; Goto F; Horiuchi R
    Eur J Clin Pharmacol; 2006 Jul; 62(7):527-33. PubMed ID: 16763826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.
    Ito K; Houston JB
    Pharm Res; 2004 May; 21(5):785-92. PubMed ID: 15180335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of metabolic clearance of bisphenol A (4,4 '-dihydroxy-2,2-diphenylpropane) using cryopreserved human hepatocytes.
    Kuester RK; Sipes IG
    Drug Metab Dispos; 2007 Oct; 35(10):1910-5. PubMed ID: 17646283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine.
    Docci L; Umehara K; Krähenbühl S; Fowler S; Parrott N
    AAPS J; 2020 Oct; 22(6):128. PubMed ID: 33033903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uridine 5'-Diphospho-glucuronosyltransferase 1A3 (UGT1A3) Prediction of Hepatic Clearance of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Substrate Telmisartan by Glucuronidation Using In Vitro-In Vivo Extrapolation (IVIVE).
    Gabor-Worwa E; Kowal-Chwast A; Gaud N; Gogola D; Littlewood P; Smoluch M; Brzózka K; Kus K
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):393-403. PubMed ID: 38642299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II.
    Borlak J; Gasparic A; Locher M; Schupke H; Hermann R
    Metabolism; 2006 Jun; 55(6):711-21. PubMed ID: 16713428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes.
    Tachibana M; Tanaka M; Masubuchi Y; Horie T
    Drug Metab Dispos; 2005 Jun; 33(6):803-11. PubMed ID: 15769885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats.
    Dalvie D; Kang P; Zientek M; Xiang C; Zhou S; Obach RS
    Chem Res Toxicol; 2008 Dec; 21(12):2260-71. PubMed ID: 19548350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
    Miners JO; Mackenzie PI; Knights KM
    Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance.
    Huang L; Berry L; Ganga S; Janosky B; Chen A; Roberts J; Colletti AE; Lin MH
    Drug Metab Dispos; 2010 Feb; 38(2):223-31. PubMed ID: 19875499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene.
    Kosaka K; Sakai N; Endo Y; Fukuhara Y; Tsuda-Tsukimoto M; Ohtsuka T; Kino I; Tanimoto T; Takeba N; Takahashi M; Kume T
    Drug Metab Dispos; 2011 Sep; 39(9):1495-502. PubMed ID: 21646435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.
    Brown HS; Griffin M; Houston JB
    Drug Metab Dispos; 2007 Feb; 35(2):293-301. PubMed ID: 17132764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic and intestinal glucuronidation of mono(2-ethylhexyl) phthalate, an active metabolite of di(2-ethylhexyl) phthalate, in humans, dogs, rats, and mice: an in vitro analysis using microsomal fractions.
    Hanioka N; Isobe T; Kinashi Y; Tanaka-Kagawa T; Jinno H
    Arch Toxicol; 2016 Jul; 90(7):1651-7. PubMed ID: 26514348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of UDP-glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs.
    Li T; Zheng Y; Fu F; Ji H; Chen X; Zhao Y; Zhao D; Li N; Zhang L
    Xenobiotica; 2011 Jul; 41(7):530-7. PubMed ID: 21524190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.
    Nishimuta H; Sato K; Yabuki M; Komuro S
    Drug Metab Pharmacokinet; 2011; 26(6):592-601. PubMed ID: 21878741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors.
    Liu SN; Lu JBL; Watson CJW; Lazarus P; Desta Z; Gufford BT
    Drug Metab Dispos; 2019 May; 47(5):535-544. PubMed ID: 30804050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
    Gaganis P; Miners JO; Knights KM
    Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney.
    Soars MG; Riley RJ; Findlay KA; Coffey MJ; Burchell B
    Drug Metab Dispos; 2001 Feb; 29(2):121-6. PubMed ID: 11159800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions.
    Lundquist P; Lööf J; Sohlenius-Sternbeck AK; Floby E; Johansson J; Bylund J; Hoogstraate J; Afzelius L; Andersson TB
    Drug Metab Dispos; 2014 Mar; 42(3):469-80. PubMed ID: 24396146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Method for predicting human intestinal first-pass metabolism of UGT substrate compounds.
    Furukawa T; Yamano K; Naritomi Y; Tanaka K; Terashita S; Teramura T
    Xenobiotica; 2012 Oct; 42(10):980-8. PubMed ID: 22540538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.